Semaglutide vs Tirzepatide: The Difference Explained

Semaglutide and tirzepatide are the two most talked-about medications in the weight-loss conversation, and people often ask which one is better. They work in related but different ways, and the "better" choice really depends on your goals, your response, and your clinician's guidance.

The Quick Version

Both are injectable medications that help regulate appetite and blood sugar, and both have brand versions approved specifically for weight management. The headline difference is how they act on your body's hormone receptors — and, on average, how much weight people lose in clinical trials.

• Semaglutide targets one hormone pathway (GLP-1).
• Tirzepatide targets two pathways (GLP-1 and GIP).

That second mechanism is a big reason tirzepatide has shown larger average weight loss in trials.

Know the Brand Names First

This is where a lot of confusion starts, because each ingredient is sold under more than one brand.

• Semaglutide is sold as Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). It's also available in compounded forms.
• Tirzepatide is sold as Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management).

So Ozempic and Mounjaro are the diabetes-approved versions used off-label for weight, while Wegovy and Zepbound are the weight-management-approved versions. For a direct product face-off, see our Zepbound vs Wegovy comparison.

How They Work

Both medications mimic gut hormones that influence appetite and fullness:

• GLP-1 (both drugs): slows digestion, reduces appetite, and helps you feel full sooner.
• GIP (tirzepatide only): a second hormone pathway that may enhance the appetite and metabolic effects.

Because tirzepatide engages two receptors instead of one, many people see stronger effects — but individual response varies, and more isn't automatically right for everyone.

What the Trials Showed

The clinical trial results give a useful benchmark, as long as you treat them as averages rather than promises:

• Semaglutide (Wegovy): about 15% average body-weight reduction over roughly 68 weeks in the STEP 1 trial.
• Tirzepatide (Zepbound): about 21% average over roughly 72 weeks in the SURMOUNT-1 trial.

On paper, tirzepatide produced greater average weight loss. But these are averages across large groups over long periods. Your own results depend on your dose, how long you stay on treatment, your body, and lifestyle factors like diet and activity. Some people do very well on semaglutide, and side effects and tolerability differ from person to person too.

Which Is "Better"?

There's no universal answer, and that's the honest takeaway. The right choice depends on several factors:

1. Your response and tolerability. The medication you can stay on comfortably often beats the one with the higher trial number.
2. What your insurance covers. Coverage differs by plan and by whether the drug is prescribed for diabetes or weight.
3. Availability and cost. Supply and price can steer the decision.
4. Your clinician's judgment. A prescriber weighing your full medical history should guide the final call.

The Cost Angle

Price often shapes the decision as much as effectiveness. Rough estimates that vary by pharmacy and program:

• Brand cash price: around $1,000 per month.
• Manufacturer self-pay or savings programs: roughly $349–$499 per month.
• Telehealth programs: approximately $199–$599 per month.
• Compounded semaglutide (cash-pay): about $149–$299 per month.

Note that compounded versions are not FDA-approved and are legally restricted once the drug is off the FDA shortage list, with quality that can vary by pharmacy. You can estimate your own out-of-pocket range with our cost calculator.

How to Decide

A practical way to approach the choice:

• Start with coverage. Check whether your plan covers either drug and under what conditions.
• Compare real prices. Look at brand, telehealth, and compounded pathways side by side.
• Factor in your goals and health history. Bigger average weight loss isn't the only variable that matters.
• Talk it through with a clinician who can match the medication to you.

If you're not sure where to begin, our find-my-GLP-1 tool can help you narrow the options based on your situation.

The Bottom Line

Semaglutide and tirzepatide are closely related but not identical. Tirzepatide showed a higher average weight-loss figure in trials, thanks partly to its dual-hormone mechanism, but semaglutide is highly effective for many people and may be more accessible or affordable depending on your plan. The "better" option is the one that fits your body, your budget, and your clinician's recommendation.

This is general information, not medical advice — talk to a licensed clinician before starting or changing any medication.